Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 6/20 | 0.62 |
| ▸ | SUZ12 | Q15022 | 6/20 | 0.62 |
| ▸ | EZH2 | Q15910 | 6/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.62 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.62 |
| ▸ | CES2 | O00748 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | CES1 | P23141 | 2/20 | 0.62 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.62 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.62 |
| ▸ | NSD1 | Q96L73 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | APAF1 | O14727 | 1/20 | 0.62 |
| ▸ | TERT | O14746 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14417727 | 0.86 | EED (0.60) | EEDSUZ12EZH2HIF1AEPAS1 | |
| SCHEMBL16023774 | 0.82 | EED (0.66) | EEDSUZ12EZH2HIF1AEPAS1 | |
| SCHEMBL16421133 | 0.80 | IDO1 (0.56) | EEDSUZ12EZH2HIF1AEPAS1 | |
| SCHEMBL29620616 | 0.78 | EED (0.51) | EEDSUZ12EZH2HIF1AEPAS1 | |
| SCHEMBL28735995 | 0.78 | EED (0.51) | EEDSUZ12EZH2HIF1AEPAS1 | |
| SCHEMBL29365561 | 0.78 | EED (0.51) | EEDSUZ12EZH2HIF1AEPAS1 | |
| SCHEMBL29754427 | 0.78 | EED (0.51) | EEDSUZ12EZH2HIF1AEPAS1 | |
| Tanshinone Iia SCHEMBL2026738 | 0.77 | EED (1.00) | EEDSUZ12EZH2HIF1AEPAS1 | |
| SCHEMBL16421134 | 0.77 | EED (0.56) | EEDSUZ12EZH2HIF1AEPAS1 | |
| SCHEMBL4114682 | 0.77 | EED (0.56) | EEDSUZ12EZH2HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118725415-A | Salvia-containing eucalyptus folic acid hydromagnesite composite material and preparation method and application thereof | 江西广源化工有限责任公司 | 2024-10-01 | — | — | CN | claimed |
| CN-118021812-A | Nidaminib targeting compositions | 北京睿创康泰医药研究院有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-119380826-B | Chinese patent medicine network pharmacology analysis method and model construction method based on multiscale information entropy | 首都医科大学附属北京朝阳医院 | 2025-04-08 | — | — | CN | disclosed |
| CN-119380826-A | Chinese patent medicine network pharmacology analysis method and model construction method based on multiscale information entropy | 首都医科大学附属北京朝阳医院 | 2025-01-28 | — | — | CN | disclosed |
| CN-118725415-A | Salvia-containing eucalyptus folic acid hydromagnesite composite material and preparation method and application thereof | 江西广源化工有限责任公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-118725415-A | Salvia-containing eucalyptus folic acid hydromagnesite composite material and preparation method and application thereof | 江西广源化工有限责任公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2024113586-A1 | METHOD FOR PREPARING GUANXINNING COMPOSITION | 神威药业集团有限公司 | 2024-06-06 | — | — | WO | disclosed |
| CN-118021812-A | Nidaminib targeting compositions | 北京睿创康泰医药研究院有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117740961-A | Compound analysis method of liquorice and liquorice probiotics fermentation preparation | 北京中医药大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-116077554-B | Preparation method of Guanxinning composition | 神威药业集团有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-116574831-A | EST-SSR molecular marker developed based on Salvia officinalis transcriptome sequence, primer and application | 青海民族大学 | 2023-08-11 | — | — | CN | disclosed |
| US-9328083-B2 | 2-aminated methylene or 2-esterified methylene tanshinone derivatives, and preparation method and application thereof | HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD. (CN) | 2016-05-03 | — | — | US | disclosed |
| US-9328083-B2 | 2-aminated methylene or 2-esterified methylene tanshinone derivatives, and preparation method and application thereof | HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD. (CN) | 2016-05-03 | — | — | US | disclosed |
| US-20150126552-A1 | 2-AMINATED METHYLENE OR 2-ESTERIFIED METHYLENE TANSHINONE DERIVATIVES, AND PREPARATION METHOD AND APPLICATION THEREOF | HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD. (CN) | 2015-05-07 | — | — | US | disclosed |
| US-20150126552-A1 | 2-AMINATED METHYLENE OR 2-ESTERIFIED METHYLENE TANSHINONE DERIVATIVES, AND PREPARATION METHOD AND APPLICATION THEREOF | HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD. (CN) | 2015-05-07 | — | — | US | disclosed |
| EP-2829880-A1 | Method for identifying modulators of BCRP/ABCG2-mediated ATP release and use of said modulators for treating diseases | Energeia Biosciences (NL) | 2015-01-28 | — | — | EP | disclosed |
| US-20140336249-A1 | 2-ALKYL-OR-ARYL-SUBSTITUTED TANSHINONE DERIVATIVES, AND PREPARATION METHOD AND APPLICATION THEREOF | HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD. (CN) | 2014-11-13 | — | — | US | disclosed |
| US-20140336249-A1 | 2-ALKYL-OR-ARYL-SUBSTITUTED TANSHINONE DERIVATIVES, AND PREPARATION METHOD AND APPLICATION THEREOF | HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD. (CN) | 2014-11-13 | — | — | US | disclosed |
| EP-2786989-A1 | 2-ALKYL-OR-ARYL-SUBSTITUTED TANSHINONE DERIVATIVES, AND PREPARATION METHOD AND APPLICATION THEREOF | Hangzhou Bensheng Pharmaceutical Co., Ltd. (CN) | 2014-10-08 | — | — | EP | disclosed |
| EP-2786990-A1 | 2-AMINATED METHYLENE OR 2-ESTERIFIED METHYLENE TANSHINONE DERIVATIVES, AND PREPARATION METHOD AND APPLICATION THEREOF | Hangzhou Bensheng Pharmaceutical Co., Ltd. (CN) | 2014-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126552-A1 | 2-AMINATED METHYLENE OR 2-ESTERIFIED METHYLENE TANSHINONE DERIVATIVES, AND PREPARATION METHOD AND APPLICATION THEREOF | NQO1, NFE2L2, NOS2 | EED 2852/4885SUZ12 2979/4885EZH2 1525/4885 |
| US-20140336249-A1 | 2-ALKYL-OR-ARYL-SUBSTITUTED TANSHINONE DERIVATIVES, AND PREPARATION METHOD AND APPLICATION THEREOF | CYP2A7, TBXAS1, CYP2J2 | EED 2035/4885SUZ12 1083/4885EZH2 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.